Q-omics provides the consensus-scored HSP90AB6P profile across patient tissues and cancer cell-line models. HSP90AB6P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HSP90AB6P is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, HSP90AB6P RNA expression shows 5,572 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, COAD, and STAD as cancer lineages where HSP90AB6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AB6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AB6P survival associations across molecular data types. HSP90AB6P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AB6P RNA expression–survival associations across cancer types. High HSP90AB6P expression shows unfavorable associations in LIHC, CHOL and CESC, but favorable associations in SKCM, ACC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HSP90AB6P RNA expression.
This table summarizes HSP90AB6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AB6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AB6P shows higher tumor expression in COAD, STAD, BRCA, LUAD, KICH and LUSC. The COAD box plot shows higher HSP90AB6P RNA expression in tumor versus normal tissue (log2 FC = +0.086, t-test p = .003).
This table shows molecular features associated with HSP90AB6P in patient tissues and cancer cell lines. In patient samples, HSP90AB6P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
